 |
PDBsum entry 5m0s
 |
|
|
 |
 |
 |
 |
Enzyme class 1:
|
 |
E.C.3.1.4.39
- alkylglycerophosphoethanolamine phosphodiesterase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
a 1-O-alkyl-sn-glycero-3-phosphoethanolamine + H2O = a 1-O-alkyl- sn-glycero-3-phosphate + ethanolamine + H+
|
 |
 |
 |
 |
 |
1-O-alkyl-sn-glycero-3-phosphoethanolamine
|
+
|
H2O
|
=
|
1-O-alkyl- sn-glycero-3-phosphate
|
+
|
ethanolamine
Bound ligand (Het Group name = )
matches with 42.86% similarity
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 2:
|
 |
E.C.3.1.4.4
- phospholipase D.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
a 1,2-diacyl-sn-glycero-3-phosphocholine + H2O = a 1,2-diacyl-sn-glycero- 3-phosphate + choline + H+
|
 |
 |
 |
 |
 |
1,2-diacyl-sn-glycero-3-phosphocholine
|
+
|
H2O
|
=
|
1,2-diacyl-sn-glycero- 3-phosphate
|
+
|
choline
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Note, where more than one E.C. class is given (as above), each may
correspond to a different protein domain or, in the case of polyprotein
precursors, to a different mature protein.
|
|
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
J Med Chem
60:2006-2017
(2017)
|
|
PubMed id:
|
|
|
|
|
| |
|
Rational Design of Autotaxin Inhibitors by Structural Evolution of Endogenous Modulators.
|
|
W.J.Keune,
F.Potjewyd,
T.Heidebrecht,
F.Salgado-Polo,
S.J.Macdonald,
L.Chelvarajan,
A.Abdel Latif,
S.Soman,
A.J.Morris,
A.J.Watson,
C.Jamieson,
A.Perrakis.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Autotaxin produces the bioactive lipid lysophosphatidic acid (LPA) and is a drug
target of considerable interest for numerous pathologies. We report the
expedient, structure-guided evolution of weak physiological allosteric
inhibitors (bile salts) into potent competitive Autotaxin inhibitors that do not
interact with the catalytic site. Functional data confirms that our lead
compound attenuates LPA mediated signaling in cells and reduces LPA synthesis in
vivo, providing a promising natural product derived scaffold for drug discovery.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
');
}
}
 |